Why target IL-31 for itch?
This review argues IL-31/IL-31R drive pruritus across skin diseases and highlights nemolizumab as the late-stage antibody against the IL-31 receptor.
Source
Interleukin-31 as a Clinical Target for Pruritus Treatment
What they did
Synthesized evidence that IL-31 (identified 2004) and its receptor contribute to itch and barrier/inflammatory signs, summarizing elevated IL-31 signaling in atopic dermatitis, prurigo nodularis, and psoriasis and surveying emerging anti-IL-31 strategies.
What they found
Elevated IL-31 or receptor levels appear in multiple pruritic diseases; serum IL-31 in atopic dermatitis tracks severity/itch. Current antipruritics are often inadequate. Among pipeline agents, only nemolizumab (anti-IL-31R mAb) had successfully completed late-stage clinical studies at the time of writing.
The limits
What it doesn't show
Narrative review—not a new RCT meta-analysis; drug landscape may have changed after 2021 publication.
Key terms
- IL-31
- T-cell-derived cytokine strongly linked to pruritus.
- IL-31RA
- IL-31 receptor alpha chain targeted by some therapies.
- Pruritus
- Itch that impairs sleep, mood, and daily function.
- Nemolizumab
- Humanized mAb against the IL-31 receptor.
- Atopic dermatitis
- Common inflammatory skin disease with prominent itch.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
IL-31 was first identified in:
Common questions
When was IL-31 identified?
2004.
Diseases with elevated IL-31 signaling examples?
Atopic dermatitis, prurigo nodularis, psoriasis.
Leading late-stage agent named?
Nemolizumab (anti-IL-31 receptor).
Clinical need emphasized?
Current antipruritic treatments are often ineffective.